ScholarIQanswers from OpenAlex
Austin Hospital
InstitutionResearch output, impact & collaborations
Austin Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Austin Hospital?
ScholarIQrecord summary
Austin Hospital is a research organisation in Melbourne, AU. OpenAlex records 10,029 works and 800,125 citations for it. 1,619 researchers list it as their most recent affiliation.
How many works does Austin Hospital have?
ScholarIQindexed works
Austin Hospital has 10,029 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Austin Hospital have?
ScholarIQcitation count
Austin Hospital has 800,125 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Austin Hospital?
ScholarIQresearcher count
Austin Hospital has 1,619 researchers in the ScholarIQ index.
What is the average h-index at Austin Hospital?
ScholarIQavg h-index
Austin Hospital has an average h-index of 46.7 in OpenAlex.
What is the ROR of Austin Hospital?
ScholarIQror
The ROR for Austin Hospital is on the source record.
What is the OpenAlex record for Austin Hospital?
ScholarIQopenalex
The OpenAlex for Austin Hospital is on the source record.
Who are the most-cited researchers behind Austin Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Austin Hospital?
ScholarIQmost cited works
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Salvatore Siena, Alice T. Shaw, Anna F. Farago, Collin M. Blakely, Takashi Seto, Byoung Chul Cho, Diégo Tosi, Benjamin Besse, Sant P. Chawla, Lyudmila Bazhenova, John C. Krauss, Young Kwang Chae, Minal Barve, Ignacio Garrido‐Laguna, Stephen V. Liu, Paul Conkling, Thomas John, Marwan Fakih, Darren Sigal, Herbert H. Loong, Gary L. Buchschacher, Pilar Garrido, Jorgé Nieva, Conor Steuer, Tobias R. Overbeck, Daniel W. Bowles, Elizabeth Fox, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, George D. Demetri
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lü, Wu‐Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz M. Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi‐Long Wu
Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee, Takayasu Kurata, Dong‐Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov, Serban Ghiorghiu, Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, Kenneth S. Thress, Pasi A. Jänne
How much of the research on Austin Hospital is open access?
ScholarIQopen access share
83%OPEN ACCESS